Composition : Ribavirin USP 200 mg.

Indications : Ribavirin is used in combination with Interferon /PegInterferon and other oral anti-viral drugs such as Sofosbuvir to treat patients with Chronic Hepatitis C (CHC).

Dosage and Administration : Ribavirin capsule is taken orally two times daily with food at a consistent manner. These indications are based on achieving unnoticeable HCV-RNA after treatment for 24 or 48 weeks and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. The Recommended dosage of Ribavirin in the combination therapy is given below : 1) The daily dose of Ribavirin + Interferon alpha-2a/Interferon alpha-2b (3 MIU 3 times weekly subcutaneously): i) ≤75 kg = (400+600) mg for 48 weeks (Genotype 1 & 4). ii) >75 kg = (600+600) mg for 24 weeks (Genotype 2 & 3). 2) Ribavirin daily dose with PegInterferon alpha-2a/ Peg-interferon alpha -2b (180 µgm once weekly subcutaneously). i) <75 kg= (600+600) mg for 48 weeks (Genotype 1 & 4). ii) (400+400) mg for 24 weeks (Genotype 2 & 3). Or, as directed by the registered physicians.

Use in pregnancy and lactation : Ribavirin must not be used during pregnancy. It is not known whether this drug passes into breast milk. Caution should be advised highly for the administration of Ribavirin to nursing women to avoid any serious adverse reactions in infants.

Packing : Opegus : 3 x 7's capsules in blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.